InsiderTrades

Form 4 for GYRE GYRE THERAPEUTICS, INC.

Accepted 2026-05-27 16:01:25 ET · period of report 2026-05-22 · accession 0001140361-26-022980 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2026-05-27 16:01 2026-05-22+ GYRE Ye Weiguo COO M - OptEx $0.75 +7,500 704.0K +1% +$5,625
DM 2026-05-27 16:01 2026-05-22+ GYRE Ye Weiguo COO S - Sale+OE $6.09 -7,500 700.0K -1% -$45.7K
DM 2026-05-27 16:01 2026-05-22+ GYRE Ye Weiguo COO M - OptEx $0.00 -7,500 897.4K -0.8% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-05-22 M A 3,500 $0.75 703,500 D — —
2 Common Common Stock 2026-05-22 S D 3,500 $6.08 700,000 D — — (F1) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.04 to $6.1051. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
3 Common Common Stock 2026-05-26 M A 4,000 $0.75 704,000 D — —
4 Common Common Stock 2026-05-26 S D 4,000 $6.10 700,000 D — —
5 Derivative Stock Option (Right to Buy) 2026-05-22 M D 3,500 $0.00 901,395 D $0.75 · — to 2030-10-31 3,500 Common Stock (F2) These options are vested in full.
6 Derivative Stock Option (Right to Buy) 2026-05-26 M D 4,000 $0.00 897,395 D $0.75 · — to 2030-10-31 4,000 Common Stock (F2) These options are vested in full.